Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in scaling up the manufacturing process. Novavax lags behind other drugmakers in the global race for COVID-19 vaccine, with shots from Pfizer and Moderna authorized for emergency use in the United States. Novavax has signed supply agreements with several countries and is set to provide 60 million doses to the UK, where a late-stage study is under way. It is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for developing and testing its potential vaccine. Novavax is also running a fully enrolled Phase 2b trial in South Africa and a Phase 1/2 continuation in the United States and Australia.

Source: Mint December 28, 2020 15:28 UTC